Загрузка...
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with...
Сохранить в:
| Опубликовано в: : | Clin Mol Hepatol |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Korean Association for the Study of the Liver
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4612290/ https://ncbi.nlm.nih.gov/pubmed/26527250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2015.21.3.287 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|